Cargando…

Optimizing Blended Collagen-Fibrin Hydrogels for Cardiac Tissue Engineering with Human iPSC-derived Cardiomyocytes

[Image: see text] Natural polymer hydrogels are used ubiquitously as scaffold materials for cardiac tissue engineering as well as for soft tissue engineering more broadly because of FDA approval, minimal immunogenicity, and well-defined physiological clearance pathways. However, the relationships be...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaiser, Nicholas J., Kant, Rajeev J., Minor, Alicia J., Coulombe, Kareen L.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372981/
https://www.ncbi.nlm.nih.gov/pubmed/30775432
http://dx.doi.org/10.1021/acsbiomaterials.8b01112
_version_ 1783394874105528320
author Kaiser, Nicholas J.
Kant, Rajeev J.
Minor, Alicia J.
Coulombe, Kareen L.K.
author_facet Kaiser, Nicholas J.
Kant, Rajeev J.
Minor, Alicia J.
Coulombe, Kareen L.K.
author_sort Kaiser, Nicholas J.
collection PubMed
description [Image: see text] Natural polymer hydrogels are used ubiquitously as scaffold materials for cardiac tissue engineering as well as for soft tissue engineering more broadly because of FDA approval, minimal immunogenicity, and well-defined physiological clearance pathways. However, the relationships between natural polymer hydrogels and resident cell populations in directing the development of engineered tissues are poorly defined. This interaction is of particular concern for tissues prepared with iPSC-derived cell populations, in which population purity and batch-to-batch variability become additional critical factors to consider. Herein, the design space for a blended fibrin and collagen scaffold is characterized for applications in creating engineered myocardium with human iPSC-derived cardiomyocytes. Stiffness values of the acellular hydrogel formulations approach those of native myocardium in compression, but deviate significantly in tension when compared to rat myocardium in both transverse and longitudinal fiber orientations. A response surface methodology approach to understanding the relationship between collagen concentration, fibrin concentration, seeding density, and cardiac purity found a statistically significant predictive model across three repeated studies that confirms that all of these factors contribute to tissue compaction. In these constructs, increased fibrin concentration and seeding density were each associated with increased compaction, while increased collagen concentration was associated with decreased compaction. Both the lowest (24.4% cTnT(+)) and highest (60.2% cTnT(+)) cardiomyocyte purities evaluated were associated with decreased compaction, whereas the greatest compaction was predicted to occur in constructs prepared with a 40–50% cTnT(+) population. Constructs prepared with purified cardiomyocytes (≥75.5% cTnT(+)) compacted and formed syncytia well, although increased fibrin concentration in these groups was associated with decreased compaction, a reversal of the trend observed in unpurified cardiomyocytes. This study demonstrates an analytical approach to understanding cell–scaffold interactions in engineered tissues and provides a foundation for the development of more sophisticated and customized scaffold platforms for human cardiac tissue engineering.
format Online
Article
Text
id pubmed-6372981
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-63729812019-02-14 Optimizing Blended Collagen-Fibrin Hydrogels for Cardiac Tissue Engineering with Human iPSC-derived Cardiomyocytes Kaiser, Nicholas J. Kant, Rajeev J. Minor, Alicia J. Coulombe, Kareen L.K. ACS Biomater Sci Eng [Image: see text] Natural polymer hydrogels are used ubiquitously as scaffold materials for cardiac tissue engineering as well as for soft tissue engineering more broadly because of FDA approval, minimal immunogenicity, and well-defined physiological clearance pathways. However, the relationships between natural polymer hydrogels and resident cell populations in directing the development of engineered tissues are poorly defined. This interaction is of particular concern for tissues prepared with iPSC-derived cell populations, in which population purity and batch-to-batch variability become additional critical factors to consider. Herein, the design space for a blended fibrin and collagen scaffold is characterized for applications in creating engineered myocardium with human iPSC-derived cardiomyocytes. Stiffness values of the acellular hydrogel formulations approach those of native myocardium in compression, but deviate significantly in tension when compared to rat myocardium in both transverse and longitudinal fiber orientations. A response surface methodology approach to understanding the relationship between collagen concentration, fibrin concentration, seeding density, and cardiac purity found a statistically significant predictive model across three repeated studies that confirms that all of these factors contribute to tissue compaction. In these constructs, increased fibrin concentration and seeding density were each associated with increased compaction, while increased collagen concentration was associated with decreased compaction. Both the lowest (24.4% cTnT(+)) and highest (60.2% cTnT(+)) cardiomyocyte purities evaluated were associated with decreased compaction, whereas the greatest compaction was predicted to occur in constructs prepared with a 40–50% cTnT(+) population. Constructs prepared with purified cardiomyocytes (≥75.5% cTnT(+)) compacted and formed syncytia well, although increased fibrin concentration in these groups was associated with decreased compaction, a reversal of the trend observed in unpurified cardiomyocytes. This study demonstrates an analytical approach to understanding cell–scaffold interactions in engineered tissues and provides a foundation for the development of more sophisticated and customized scaffold platforms for human cardiac tissue engineering. American Chemical Society 2018-12-10 2019-02-11 /pmc/articles/PMC6372981/ /pubmed/30775432 http://dx.doi.org/10.1021/acsbiomaterials.8b01112 Text en Copyright © 2018 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Kaiser, Nicholas J.
Kant, Rajeev J.
Minor, Alicia J.
Coulombe, Kareen L.K.
Optimizing Blended Collagen-Fibrin Hydrogels for Cardiac Tissue Engineering with Human iPSC-derived Cardiomyocytes
title Optimizing Blended Collagen-Fibrin Hydrogels for Cardiac Tissue Engineering with Human iPSC-derived Cardiomyocytes
title_full Optimizing Blended Collagen-Fibrin Hydrogels for Cardiac Tissue Engineering with Human iPSC-derived Cardiomyocytes
title_fullStr Optimizing Blended Collagen-Fibrin Hydrogels for Cardiac Tissue Engineering with Human iPSC-derived Cardiomyocytes
title_full_unstemmed Optimizing Blended Collagen-Fibrin Hydrogels for Cardiac Tissue Engineering with Human iPSC-derived Cardiomyocytes
title_short Optimizing Blended Collagen-Fibrin Hydrogels for Cardiac Tissue Engineering with Human iPSC-derived Cardiomyocytes
title_sort optimizing blended collagen-fibrin hydrogels for cardiac tissue engineering with human ipsc-derived cardiomyocytes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372981/
https://www.ncbi.nlm.nih.gov/pubmed/30775432
http://dx.doi.org/10.1021/acsbiomaterials.8b01112
work_keys_str_mv AT kaisernicholasj optimizingblendedcollagenfibrinhydrogelsforcardiactissueengineeringwithhumanipscderivedcardiomyocytes
AT kantrajeevj optimizingblendedcollagenfibrinhydrogelsforcardiactissueengineeringwithhumanipscderivedcardiomyocytes
AT minoraliciaj optimizingblendedcollagenfibrinhydrogelsforcardiactissueengineeringwithhumanipscderivedcardiomyocytes
AT coulombekareenlk optimizingblendedcollagenfibrinhydrogelsforcardiactissueengineeringwithhumanipscderivedcardiomyocytes